Form 4: Ionis Pharmaceuticals Executive Exercises Stock Options and Sells Shares

An Ionis Pharmaceuticals executive, C. Frank Bennett, exercised stock options and sold shares to cover tax obligations, while also receiving new restricted stock units.

Summary

• C. Frank Bennett, an Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals, engaged in multiple transactions involving the company's stock.
• On January 15, 2025, Bennett acquired 18,011 shares of common stock through the vesting of restricted stock units.
• Also on January 15, 2025, Bennett was granted 22,000 performance restricted stock units (PRSUs) and 33,000 restricted stock units (RSUs).
• On January 16, 2025, Bennett sold 6,752 shares of common stock at a weighted average price of $32.896 per share to cover tax obligations.
• Following these transactions, Bennett directly owns 90,866 shares of common stock, 63,482 PRSUs, and 56,500 RSUs.

Sentiment

Score: 6

Explanation: The document reflects standard executive compensation practices. While the sale of shares could be seen as slightly negative, the overall sentiment is neutral to slightly positive due to the vesting of shares and the grant of new equity.

Positives

• The vesting of restricted stock units indicates that performance milestones were likely met.
• The grant of new PRSUs and RSUs suggests continued confidence in the executive's performance and the company's future.

Negatives

• The sale of 6,752 shares, while for tax obligations, could be perceived negatively by some investors as a reduction in the executive's direct holdings.

Risks

• The vesting of PRSUs is contingent on the company's performance relative to its peers, introducing uncertainty.
• The actual number of PRSUs that will vest could be significantly lower than the maximum stated.

Future Outlook

The performance restricted stock units (PRSUs) may vest at the end of a three-year performance period based on the company's total shareholder return compared to a peer group. The restricted stock units (RSUs) vest in four equal annual installments.

Management Comments

• The sale was made pursuant to an automatic sale to cover the required tax withholding obligations.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Industry Context

This type of stock transaction is common for executives in publicly traded companies as part of their compensation packages. The vesting of stock options and the subsequent sale to cover taxes are standard practices.

Comparison to Industry Standards

• Stock-based compensation, including restricted stock units and performance-based units, is a common practice among biotechnology and pharmaceutical companies like Ionis.
• Companies such as Alnylam Pharmaceuticals and Biogen also use similar equity-based compensation structures to incentivize and retain key executives.
• The vesting schedules and performance metrics tied to these units are generally aligned with industry norms, focusing on long-term value creation and shareholder returns.

Stakeholder Impact

• Shareholders may view the sale of shares as a slight negative, but the overall impact is likely to be minimal.
• Employees may see the vesting of stock options and the grant of new equity as a positive sign of the company's performance and future prospects.

Next Steps

• The performance restricted stock units will vest based on the company's performance over the next three years.
• The restricted stock units will vest in four equal annual installments.

Key Dates

Keywords

Ionis Pharmaceuticals, stock options, restricted stock units, performance restricted stock units, insider trading, executive compensation, share sale, vesting